CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer

Published:2019-04 Issue: Volume:447 Page:130-140
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Zhang Kai,Hong Ruoxi,Kaping Lee,Xu Fei,Xia Wen,Qin Ge,Zheng Qiufan,Lu Qianyi,Zhai Qinglian,Shi Yanxia,Yuan Zhongyu,Deng Wuguo,Chen Miao,Wang Shusen

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Breast cancer statistics, 2013;DeSantis;Ca - Cancer J. Clin.,2014

2. Global cancer statistics, 2012;Torre;Ca - Cancer J. Clin.,2015

3. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor;Tzahar;Mol. Cell Biol.,1996

4. The ErbB signaling network: receptor heterodimerization in development and cancer;Olayioye;EMBO J.,2000

5. The evolving landscape of HER2 targeting in breast cancer;Moasser;JAMA Oncol.,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of targeting CDK4/6 in cancer immunotherapy;Holistic Integrative Oncology;2024-06-27

2. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities;Acta Pharmacologica Sinica;2024-02-15

3. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer;Frontiers in Oncology;2024-01-16

4. Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer;Signal Transduction and Targeted Therapy;2023-12-18

5. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway;Communications Biology;2023-10-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3